Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
BMJ Open
|
July 30, 2015
Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
Saskia de Groot, Adriana J Rijnsburger, Matthijs M Versteegh, et al.
Frontiers in Neurology
|
November 17, 2022
Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, et al.
European Journal of Haematology
|
April 21, 2015
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model
Hedwig M Blommestein, Silvia G R Verelst, Saskia de Groot, et al.
Pharmacoeconomics
|
September 9, 2018
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Nasuh C Büyükkaramikli, Saskia de Groot, Rob Riemsma, et al.
Urology
|
May 16, 2016
Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry
Saskia de Groot, William K Redekop, Stefan Sleijfer, et al.
Pharmacoeconomics
|
June 24, 2020
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines
Bogdan Grigore, Oriana Ciani, Florian Dams, et al.
Pharmacoeconomics
|
May 10, 2013
Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence
Chantal W M van Gils, Saskia de Groot, William K Redekop, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2024
The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, et al.
International Journal of Technology Assessment in Health Care
|
April 26, 2021
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
Benedetta Pongiglione, Aleksandra Torbica, Hedwig Blommestein, et al.
Pharmacoeconomics
|
November 1, 2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
Nasuh C Büyükkaramikli, Saskia de Groot, Debra Fayter, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
BMJ Open
|
July 30, 2015
Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
Saskia de Groot, Adriana J Rijnsburger, Matthijs M Versteegh, et al.
Frontiers in Neurology
|
November 17, 2022
Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, et al.
European Journal of Haematology
|
April 21, 2015
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model
Hedwig M Blommestein, Silvia G R Verelst, Saskia de Groot, et al.
Pharmacoeconomics
|
September 9, 2018
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Nasuh C Büyükkaramikli, Saskia de Groot, Rob Riemsma, et al.
Urology
|
May 16, 2016
Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry
Saskia de Groot, William K Redekop, Stefan Sleijfer, et al.
Pharmacoeconomics
|
June 24, 2020
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines
Bogdan Grigore, Oriana Ciani, Florian Dams, et al.
Pharmacoeconomics
|
May 10, 2013
Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence
Chantal W M van Gils, Saskia de Groot, William K Redekop, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 10, 2024
The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, et al.
International Journal of Technology Assessment in Health Care
|
April 26, 2021
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal
Benedetta Pongiglione, Aleksandra Torbica, Hedwig Blommestein, et al.
Pharmacoeconomics
|
November 1, 2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
Nasuh C Büyükkaramikli, Saskia de Groot, Debra Fayter, et al.
Page
of 3